Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863207 · ClinicalTrials.gov registry record · NA
Autonomic Reactivity and Personalized Neurostimulation
A NA study of Functional Dyspepsia and Dysautonomia, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06863207: Recruiting NA study of Functional Dyspepsia and Dysautonomia, sponsored by Medical College of Wisconsin.
NCT06863207 is a NA study of Functional Dyspepsia and Dysautonomia that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 120 participants, above the 60-participant average among 9 other Functional Dyspepsia trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06863207, a NA study of Functional Dyspepsia and Dysautonomia, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'benign, functional disorders' and treated with empiric antidepressants despite lack of scientific support and risks of serious side effects. Little is known about the underlying brain-gut mechanisms linking these comorbidities. A lack of targeted treatment options naturally follows the paucity of mechanistic data. A dysregulated ANS response circuit via brainstem nuclei is linked to visceral hypersensitivity. As the team's prior research has shown, ANS regulation can be non-invasively measured via several validated indices of cardiac vagal tone. Using the novel vagal efficiency (VE) metric, the investigators have demonstrated inefficient vagal regulation in cyclic vomiting syndrome and pain-related DGBI and that low VE predicts response to non-invasive, auricular percutaneous electrical nerve field stimulation (PENFS) therapy. PENFS targets brainstem vagal afferent pathways and, along with brain-gut interventions such as hypnotherapy, are the only therapies currently proven effective for pediatric DGBI. Individualizing neurostimulation based on sensory thresholds while assessing dynamic ANS reactivity offers a path towards personalized medicine using the most effective therapies to date. This proposal will test the feasibility of an ANS tracking software in assessing real-time, autonomi
Primary Outcome
Validated quality of life instrument assessing physical, emotional, and psychosocial functioning in children across 6 domains (subscales). Scores range from 0 (minimum) to 5 (maximum). A lower score indicates improved quality of life for the Anxiety, Depression, Fatigue and Pain Interference domains/subscales. A higher scores indicates improvement in the Physical Function and Peer Relationships subscales. Scores are converted to a T-score where a score of 50 represents the mean.
Conditions Studied
Interventions
- DEVICE Percutaneous electrical nerve field stimulation
- BEHAVIORAL Hypnotherapy
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2029-06 |
| Phase | NA |
What NCT06863207 shows while recruiting
NCT06863207 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 9 other Functional Dyspepsia trials with a reported enrollment target (100% higher).
The record links to 4 conditions, with Functional Dyspepsia appearing as the primary indexed condition, and to 2 interventions - of which Percutaneous electrical nerve field stimulation is the first listed.
NCT06863207 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06863207 about?
NCT06863207 is a clinical study titled "Autonomic Reactivity and Personalized Neurostimulation". Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsi...
What is the current status of trial NCT06863207?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-01-24. Estimated completion is 2029-06.
What conditions does trial NCT06863207 study?
This clinical trial studies the following conditions: Functional Dyspepsia, Dysautonomia, Cyclic Vomiting Syndrome, Functional Gastrointestinal Disorders (FGIDs).
What interventions are being tested in trial NCT06863207?
The interventions under investigation include: Percutaneous electrical nerve field stimulation (DEVICE), Hypnotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06863207?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863207 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Functional Dyspepsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06863207's enrollment target sits among peer trials
120 2nd of 9 the highest of 9 other Functional Dyspepsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Functional Dyspepsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia
RECRUITING · NA
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
Functional Dyspepsia Treatment Using Virtual Reality
RECRUITING · NA
-
Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)
RECRUITING · NA
-
Cerebral Cortical Influences on Autonomic Function
ACTIVE NOT RECRUITING · NA
-
Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI